Antiviral prodrugs - The development of successful prodrug strategies for antiviral chemotherapy

British Journal of Pharmacology

Volumn 147, Issue 1, 2006, Pages 1-11

  De Clercq, Erik ^a   Field, Hugh J ^b  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Adefovir prodrug; Antiviral prodrugs; Cidofovir prodrugs; Famciclovir; Tenofovir prodrug; Valaciclovir; Valganciclovir

Indexed keywords

2' O ALANYLACICLOVIR; 2' O GLYCYLACICLOVIR; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUORO 2',3' DIDEOXYGUANOSINE; 3' FLUOROTHYMIDINE; 5 (2 BROMOVINYL) 2' DEOXYURIDINE; 9 [4 HYDROXY 2 (HYDROXYMETHYL)BUTYL]GUANINE; ACICLOVIR DERIVATIVE; ADEFOVIR; ANTIVIRUS AGENT; BETA LEVO 2' DEOXYCYTIDINE; BIS[5' O [2 (VALOYLOXY)PROPIONYL]] 2',3' DIDEOXYNUCLEOSIDE; CIDOFOVIR; DIDANOSINE; FAMCICLOVIR; GANCICLOVIR; MIV 210; NUCLEOSIDE DERIVATIVE; OSELTAMIVIR; PENCICLOVIR; SIALIDASE INHIBITOR; STAVUDINE; TELBIVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; VALGANCICLOVIR; VALTORCITABINE; ZALCITABINE; ZANAMIVIR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SOLUBILITY; DRUG STRUCTURE; HUMAN; NEPHROTOXICITY; NONHUMAN; OINTMENT; PLASMA HALF LIFE; PRIORITY JOURNAL; REVIEW; SLOW RELEASE FORMULATION; VIRUS INFECTION;

ANIMALS; ANTIVIRAL AGENTS; HUMANS; PRODRUGS; VIRUS DISEASES;

EID: 30344486584     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706446     Document Type: Review

References (80)

1. ABELE, G., ERIKSSON, B., HARMENBERG, J. & WAHREN, B. (1988). Inhibition of varicella-zoster virus-induced DNA polymerase by a new guanosine analog, 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine triphosphate. Antimicrob. Agents Chemother., 32, 1137-1142.
2. ABELE, G., KARLSTRÖM, A., HARMENBERG, J., SHIGETA, S., LARSSON, A., LINDBORG, B. & WAHREN, B. (1987). Inhibiting effect of (RS)-9-[4-hydroxy-2- (hydroxymethyl)butyl]guanine on varicella-zoster virus replication in cell culture. Antimicrob. Agents Chemother., 31, 76-80.
3. ALDERN, K.A., CIESLA, S.L., WINEGARDEN, K.L. & HOSTETLER, K.Y. (2003). Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-14C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol. Pharmacol., 63, 678-681.
4. BALZARINI, J., BABA, M., PAUWELS, R., HERDEWIJN, P., WOOD, S.G., ROBINS, M.J. & DE CLERCQ, E. (1988). Potent and selective activity of 3′-azido-2,6-diaminopurine-2′,3′-dideoxyriboside, 3′-fluoro-2,6-diaminopurine-2′,3′-dideoxyriboside, and 3′-fluoro-2′,3′-dideoxyguanosine against human immunodeficiency virus. Mol. Pharmacol., 33, 243-249.
5. BALZARINI, J., HOLÝ, A., JINDRICH, J., NAESENS, L., SNOECK, R., SCHOLS, D. & DE CLERCQ, E. (1993). Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob. Agents Chemother., 37, 332-338.
6. BALZARINI, J., NAESENS, L., HERDEWIJN, P., ROSENBERG, I., HOLÝ, A., PAUWELS, R., BABA, M., JOHNS, D.G. & DE CLERCQ, E. (1989). Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proc. Natl. Acad. Sci. U.S.A., 86, 332-336.
7. BEADLE, J.R., HARTLINE, C., ALDERN, K.A., RODRIGUEZ, N., HARDEN, E., KERN, E.R. & HOSTETLER, K.Y. (2002). Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob. Agents Chemother., 46, 2381-2386.
8. BEUTNER, K.R., FRIEDMAN, D.J., FORSZPANIAK, C., ANDERSEN, P.L. & WOOD, M.J. (1995). Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob. Agents Chemother., 39, 1546-1553.
9. BIDANSET, D.J., BEADLE, J.R., WAN, W.B., HOSTETLER, K.Y. & KERN, E.R. (2004). Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection. J. Infect. Dis., 190, 499-503.
10. BISCHOFBERGER, N., HITCHCOCK, M.J.M., CHEN, M.S., BARKHIMER, D.B., CUNDY, K.C., KENT, K.M., LACY, S.A., LEE, W.A., LI, Z.-H., MENDEL, D.B., SMEE, D.F. & SMITH, J.L. (1994). 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)- methyl]cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2- phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo. Antimicrob. Agents Chemother., 38, 2387-2391.
11. BOURNE, N., BRAVO, F.J. & BERNSTEIN, D.I. (2000). Cyclic HPMPC is safe and effective against systemic guinea pig cytomegalovirus infection in immune compromised animals. Antiviral. Res., 47, 103-109.
12. BOYD, M.R., BACON, T.H., SUTTON, D. & COLE, M. (1987). Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL39123) in cell culture. Antimicrob. Agents Chemother., 31, 1238-1242.
13. BRYANT, M.L., BRIDGES, E.G., PLACIDI, L., FARAJ, A., LOI, A.-G., PIERRA, C., DUKHAN, D., GOSSELIN, G., IMBACH, J.-L., HERNANDEZ, B., JUODAWLKIS, A., TENNANT, B., KORBA, B., COTE, P., MARION, P., CRETTON-SCOTT, E., SCHINAZI, R.F. & SOMMADOSSI, J.-P. (2001). Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob. Agents Chemother., 45, 229-235.
14. BULLER, R.M., OWENS, G., SCHRIEWER, J., MELMAN, L., BEADLE, J.R. & HOSTETLER, K.Y. (2004). Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology, 318, 474-481.
15. CARRINGTON, D. (1994). Prospects for improved efficacy with antiviral prodrugs. Will valaciclovir and famciclovir meet the clinical challenge ? Int. Antiviral News, 2, 50-53.
16. CARRINGTON, D. (1997). Valaciclovir and famciclovir under the clinical microscope - have improvements in antiviral efficacy been realized ? Int. Antiviral News, 5, 53-57.
17. CIESLA, S.L., TRAHAN, J., WAN, W.B., BEADLE, J.R., ALDERN, K.A., PAINTER, G.R. & HOSTETLER, K.Y. (2003). Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res., 59, 163-171.
18. COLLA, L., DE CLERCQ, E., BUSSON, R. & VANDERHAEGHE, H. (1983). Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine]. J. Med. Chem., 26, 602-604.
19. COREY, L., WALD, A., PATEL, R., SACKS, S.L., TYRING, S.K., WARREN, T., DOUGLAS JR, J.M., PAAVONEN, J., MORROW, R.A., BEUTNER, K.R., STRATCHOUNSKY, L.S., MERTZ, G., KEENE, O.N., WATSON, H.A., TAIT, D., VARGAS-CORTES, M. & Valacyclovir HSV Transmission Study Group (2004). Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N. Engl. J. Med., 350, 11-20.
20. CROOKS, R.J. (1995). Valaciclovir - a review of its potential in the management of genital herpes. Antiviral Chem. Chemother., 6 (Suppl. 1), 39-44.
21. CRUMPACKER, C.S. (1996). Ganciclovir. N. Engl. J. Meet., 335, 721-729.
22. CUNDY, K.C., BARDITCH-CROVO, P., PETTY, B.G., RUBY, A., REDPATH, M., JAFFE, H.S. & LIETMAN, P.S. (1999). Clinical pharmacokinetics of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother., 43, 271-277.
23. DARBY, G. (1995). In search of the perfect antiviral. Antiviral Chem. Chemother., 6 (Suppl. 1), 54-63.
24. DE CLERCQ, E. (2003). Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin. Microbiol. Rev., 16, 569-596.
25. DE CLERCQ, E. (2004). Antiviral drugs in current clinical use. J. Clin. Virol., 30, 115-133.
26. DE CLERCQ, E., HOLÝ, A., ROSENBERG, I., SAKUMA, T., BALZARINI, J. & MAUDGAL, P.C. (1986). A novel selective broad-spectrum anti-DNA virus agent. Nature, 323, 464-467.
27. DE CLERCQ, E., SAKUMA, T., BABA, M., PAUWELS, R., BALZARINI, J., ROSENBERG, I. & HOLÝ, A. (1987). Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res., 8, 261-272.
28. DEGREEF, H. & Famciclovir Herpes Zoster Clinical Study Group (1994). Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int. J. Antimicrob. Agents, 4, 241-246.
29. DEJESUS, E., WALD, A., WARREN, T., SCHACKER, T.W., TROTTIER, S., SHAHMANESH, M., HILL, J.L. & BRENNAN, C.A. (2003). Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. J. Infect. Dis., 188, 1009-1016.
30. EARNSHAW, D.L., BACON, T.H., DARLISON, S.J., EDMONDS, K., PERKINS, R.M. & VERE HODGE, R.A. (1992). Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob. Agents Chemother., 36, 2747-2757.
31. ELION, G.B., FURMAN, P.A., FYFE, J.A., DE MIRANDA, P., BEAUCHAMP, L. & SCHAEFFER, H.J. (1977). Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. Proc. Natl. Acad. Sci. U.S.A., 74, 5716-5720.
32. FIELD, H.J. (1996). Famciclovir - origins, progress and prospects. Expert Opin. Invest. Drugs, 5, 925-938.
33. FIELD, H.J. & DE CLERCQ, E. (2004). Antiviral drugs - a short history of their discovery and development. Microbiol. Today, 31, 58-61.
34. FIELD, H.J., TEWARI, D., SUTTON, D. & THACKRAY, A.M. (1995). Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression model. Antimicrob. Agents Chemother., 39, 1114-1119.
35. GALLANT, J.E., STASZEWSKI, S., POZNIAK, A.L., DEJESUS, E., SULEIMAN, J.M.A.H., MILLER, M.D., COAKLEY, D.F., LU, B., TOOLE, J.J. & CHENG, A.K. (2004). Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-nai've patients. A 3-year randomized trial. JAMA, 292, 191-201.
36. GUO, A., HU, P., BALIMANE, P.V., LEIBACH, F.H. & SINKO, P.J. (1999). Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. J. Pharmacol. Exp. Ther., 289, 448-454.
37. HADZIYANNIS, S.J., TASSOPOULOS, N.C., HEATHCOTE, E.J., CHANG, T.-T., KITIS, G., RIZZETTO, M., MARCELLIN P LIM, S.G., GOODMAN, Z., WULFSOHN, M.S., XIONG, S., FRY, J. & BROSGART, C.L. (2003). Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med., 348, 800-807.
38. HARNDEN, M.R. & JARVEST, R.L. (1985). An improved synthesis of the antiviral acyclonucleoside 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine. Tetrahedron Lett., 26, 4265-4268.
39. HARNDEN, M.R., JARVEST, R.L., BOYD, M.R., SUTTON, D. & VERE HODGE, R.A. (1989). Prodrugs of the selective antiherpesvirus agent 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine (BRL 39123) with improved gastrointestinal absorption properties. J. Med. Chem., 32, 1738-1743.
40. HERDEWIJN, P., BALZARINI, J., DE CLERCQ, E., PAUWELS, R., BABA, M., BRODER, S. & VANDERHAEGHE, H. (1987). 3′-Substituted 2′,3′-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents. J. Med. Chem., 30, 1270-1278.
41. HERNANDEZ-SANTIAGO, B., PLACIDI, L., CRETTON-SCOTT, E., FARAJ, A., BRIDGES, E.G., BRYANT, M.L., RODRIGUEZ-ORENGO, J., IMBACH, J.L., GOSSELIN, G., PIERRA, C., DUKHAN, D. & SOMMADOSSI, J.P. (2002). Pharmacology of β-L-thymidine and β-L-2′-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. Antimicrob. Agents Chemother., 46, 1728-1733.
42. KERN, E.R., COLLINS, D.J., WAN, W.B., BEADLE, J.R., HOSTETLER, K.Y & QUENELLE, D.C. (2004). Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. Antimicrob. Agents Chemother., 48, 3516-3522.
43. KIM, C.U., LEW, W., WILLIAMS, M.A., LIU, H., ZHANG, L., SWAMINATHAN, S., BISCHOFBERGER, N., CHEN, M.S., MENDEL, D.B., TAI, C.Y., LAVER, W.O. & STEVENS, R.C. (1997). Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc., 119, 681-690.
44. KIM, I., CHU, X.-Y., KIM, S., PROVODA, C.J., LEE, K.-D. & AMIDON, G.L. (2003). Identification of a human valacyclovirase. J. Biol. Chem., 278, 25348-25356.
45. LAKE-BAKAAR, D.M., ABELE, G., LINDBORG, B., SOIKE, K.F. & DATEMA, R. (1988). Pharmacokinetics and antiviral activity in simian varicella virus-infected monkeys of (R,S)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine, an anti-varicella-zoster virus drug. Antimicrob. Agents Chemother., 32, 1807-1812.
46. LOWE, D.M., ALDERTON, W.K., ELLIS, M.R., PARMAR, V., MILLER, W.H., ROBERTS, G.B., FYFE, J.A., GAILLARD, R., ERTL P SNOWDEN, W. & LITTLER, E. (1995). Mode of action of (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine against herpesviruses. Antimicrob. Agents Chemother., 39, 1802-1808.
47. MARCELLIN, P., CHANG, T.-T., LIM, S.G., TONG, M.J., SIEVERT, W., SHIFFMAN, M.L., JEFFERS, L., GOODMAN, Z., WULFSOHN, M.S., XIONG, S., FRY, J. & BROSGART, C.L. (2003). Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med., 348, 808-816.
48. MAUDGAL, P.C., DE CLERCQ, E., DESCAMPS, J. & MISSOTTEN, L. (1984). Topical treatment of experimental herpes simplex keratouveitis with 2′-O-glycylacyclovir. Arch. Ophthalmol., 102, 140-142.
49. MENDEL, D.B., CIHLAR, T., MOON, K. & CHEN, M.S. (1997). Conversion of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine to cidofovir by an intracellular cyclic CMP phosphodiesterase. Antimicrob. Agents Chemother., 41, 641-646.
50. MERTZ, G.L., LOVELESS, M.O., LEVIN, M.J., KRAUS, S.J., FOWLER, S.L., GOADE, D. & TYRING, S.K. (1997). Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women: a multicenter, double-blind, placebo-controlled trial. Arch. Intern. Med., 157, 343-349.
51. NAESENS, L., BALZARINI, J., BISCHOFBERGER, N. & DE CLERCQ, E. (1996). Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl) adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob. Agents Chemother., 40, 22-28.
52. NAESENS, L., BISCHOFBERGER, N., AUGUSTIJNS, P., ANNAERT, P., VAN DEN MOOTER, G., ARIMILLI, M.N., KIM, C.U. & DE CLERCQ, E. (1998). Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2- phosphonyl-methoxypropyl)adenine in mice. Antimicrob. Agents Chemother., 42, 1568-1573.
53. NG, T.I., SHI, Y., HUFFAKER, J., KATI, W., LIU, Y., CHEN, C.-M., LIN, Z., MARING, C., KOHLBRENNER, W.E. & MOLLA, A. (2001). Selection and characterization of varicella-zoster virus variants resistant to (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine. Antimicrob. Agents Chemother., 45, 1629-1636.
54. PAINTER, G.R. & HOSTETLER, K.Y (2004). Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends Biotechnol., 22, 423-427.
55. PAUWELS, R., BALZARINI, J., SCHOLS, D., BABA, M., DESMYTER, J., ROSENBERG, I., HOLÝ, A. & DE CLERCQ, E. (1988). Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob. Agents Chemother., 32, 1025-1030.
56. PERRY, C.M. & FAULDS, D. (1996). Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs. 52, 754-772.
57. PRUSOFF, W.H. (1959). Synthesis and biological activities of iododeoxyuridine, an analog of thymidine. Biochim. Biophys. Acta, 32, 295-296.
58. PURIFOY, D.J., BEAUCHAMP, L.M., DE MIRANDA, P., ERTL, P., LACEY, S., ROBERTS, G., RAHIM, S.G., DARBY, G., KRENITSKY, T.A. & POWELL, K.L. (1993). Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus. J. Med. Virol., 41 (Suppl. 1), 139-145.
59. RASHIDI, M.R., SMITH, J.A., CLARKE, S.E. & BEEDHAM, C. (1997). In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. Drug Metab. Disp., 25, 805-813.
60. SACKS, S.L., AOKI, F.Y., DIAZ-MITOMA, F., SELLORS, J. & SHAFRAN, S.D. (1996). Patient-initiated, twice daily oral famciclovir for early recurrent genital herpes - a randomized, double-blind multicenter trial. JAMA, 276, 44-49.
61. SCHACKER, T., HU, H.-L., KOELLE, D.M., ZEH, J., SALTZMAN, R., BOON, R., SHAUGHNESSY, M., BARNUM, G. & COREY, L. (1998). Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. Ann. Intern. Med., 128, 21-28.
62. SCHAEFFER, H.J., BEAUCHAMP, L., DE MIRANDA, P., ELION, G.B., BAUER, D.J. & COLLINS, P. (1978). 9-(2-Hydroxyethoxymethyl)-guanine activity against viruses of the herpes group. Nature, 272, 583-585.
63. SHAFRAN, S.D., TYRING, S.K., ASHTON, R., DECROIX, J., FORSZPANIAK, C., WADE, A., PAULET, C. & CANDAELE, D. (2004). Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. J. Clin. Virol., 29, 248-253.
64. SMEE, D.F., WONG, M.-H., BAILEY, K.W., BEADLE, J.R., HOSTETLER, K.Y. & SIDWELL, R.W. (2004). Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice. Int. J. Antimicrob. Agents, 23, 430-437.
65. SOIKE, K.F., BOHM, R., HUANG, J.-L. & ÖBERG, B. (1993). Efficacy of (-)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine in African green monkeys infected with simian varicella virus. Antimicrob. Agents Chemother., 37, 1370-1372.
66. SPRUANCE, S.L., JONES, T.M., BLATTER, M.M., VARGAS-CORTES, M., BARBER, J., HILL, J., GOLDSTEIN, D., SCHULTZ, M. & Valacyclovir Cold Sore Study Group (2003). High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob. Agents Chemother., 47, 1072-1080.
67. THACKRAY, A.M. & FIELD, H.J. (1998). Famciclovir and valaciclovir differ in the prevention of herpes simplex virus type 1 latency in mice: a quantitative study. Antimicrob. Agents Chemother., 42, 1555-1562.
68. THACKRAY, A.M. & FIELD, H.J. (1996). Comparison of effects of famciclovir and valaciclovir on pathogenesis of herpes simplex virus type 2 in a murine infection model. Antimicrob. Agents Chemother., 40, 846-851.
69. THACKRAY, A.M. & FIELD, H.J. (2000). Persistence of infectious herpes simplex virus type 2 in the nervous system in mice after antiviral chemotherapy. Antimicrob. Agents Chemother., 44, 97-102.
70. TYRING, S., BARBARASH, R.A., NAHLIK, J.E., CUNNINGHAM, A., MARLEY, J., HENG, M., JONES, T., REA, T., BOON, R. & SALTZMAN, R. (1995). Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med., 123, 89-96.
71. VAN BÖMMEL, F., WÜNSCHE, T., MAUSS, S., REINKE, P., BERGK, A., SCHÜRMANN, D., WIEDENMANN, B. & BERG, T. (2004). Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology, 40, 1421-1425.
72. VAN GELDER, J., DEFERME, S., NAESENS, L., DE CLERCQ, E., VAN DEN MOOTER, G., KINGET, R. & AUGUSTIJNS, P. (2002). Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. Drug Metab. Disp., 30, 924-930.
73. VERE HODGE, R.A. & CHENG, Y.C. (1993a). Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir. Antiviral Chem. Chemother., 4, 67-84.
74. VERE HODGE, R.A. & CHENG, Y.C. (1993b). The mode of action of penciclovir. Antiviral Chem. Chemother., 4 (Suppl. 1), 13-24.
75. VERE HODGE, R.A. & PERKINS, R.M. (1989). Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob. Agents Chemother., 33, 223-229.
76. VERE HODGE, R.A. (1993). Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir. Antiviral Chem. Chemother., 4, 67-84.
77. VERB HODGE, R.A., SUTTON, D., BOYD, M.R., HARNDEN, M.R. & JARVEST, R.L. (1989). Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine; penciclovir]. Antimicrob. Agents Chemother., 33, 1765-1773.
78. VON ITZSTEIN, M., WU , W.-Y., KOK, G.B., PEGG, M.S., DYASON, J.C., JIN, B., VAN PHAN, T., SMYTHE, M.L., WHITE, H.F., OLIVER, S.W., COLMAN, P.M., VARGHESE, J.N., RYAN, D.M., WOOD, J.M., BETHELL, R.C., HOTHAM, V.J., CAMERON, J.M. & PENN, C.R. (1993). Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature, 363, 418-423.
79. WELLER, S., BLUMM, M.R., DOUCETTE, M., BURNETTE, T., CEDERBERG, D.M., DE MIRANDA, P & SMILEY, M.L. (1993). Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single, and multiple dose administration to normal volunteers, Clin. Phurmacol. Ther., 54, 595-605.
80. WUTZLER, P. & THUST, R. (2001). Genetic risks of antiviral nucleoside analogues - a survey. Antiviral Res., 49, 55-74.